Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

Marech,Ilaria; Vacca,Angelo; Sivestris,Nicola; Gnoni,Antonio; Lorusso,Vito

doi:10.3892/ol.2013.1275

June 2013 Volume 5 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June 2013 Volume 5 Issue 6

Full Size Image

Case Report

Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

Authors:
- Ilaria Marech
- Angelo Vacca
- Nicola Sivestris
- Antonio Gnoni
- Vito Lorusso
View Affiliations / Copyright

Affiliations: Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy, Medical Oncology Unit, National Cancer Research Centre, Giovanni Paolo II Tumor Institute, Bari, Italy, Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
Pages: 1877-1880
|
Published online on: March 29, 2013

https://doi.org/10.3892/ol.2013.1275
Expand metrics +

Abstract

Docetaxel is the current first-line treatment for castration-resistant prostate cancer (CRPC), following failure to respond to maximal androgen blockade (MAB). Patients who fail to respond to docetaxel may receive cabazitaxel or abiraterone; however, there are no recommendations on which of these two agents should be used first. Here, we present a case of a male patient suffering from CRPC with liver and lymph node metastases, in which abiraterone achieved a partial response, according to RECIST criteria. In the literature, visceral involvement in patients with advanced prostate cancer is an infrequent occurrence; it affects 18‑22% of patients. In the pivotal study concerning docetaxel-resistant patients, abiraterone was compared with a placebo and the forest plot for survival demonstrated that patients with visceral involvement have significantly benefited from abiraterone. In the TROPIC trial comparing cabazitaxel with mitoxantrone, the proportion of patients with visceral disease was ~25% in both arms and there was no difference in overall survival in this subgroup of patients. In our case, we observed a significant activity of abiraterone in lymph node and liver metastases. If confirmed in large studies, this observation may raise concerns over whether to treat patients suffering from CRPC and visceral metasis with chemotherapy or hormone therapy.

View Figures

View References

1	Siegel R, Desantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
2	Arcangeli S, Pinzi V and Arcangeli G: Epidemiology of prostate cancer and treatment remarks. World J Radiol. 4:241–246. 2012. View Article : Google Scholar : PubMed/NCBI
3	Singh SM, Gauthier S and Labrie F: Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 7:211–224. 2000. View Article : Google Scholar : PubMed/NCBI
4	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
5	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
6	De Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 376:1147–1154. 2010.
7	De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011.
8	Attard G, Reid AH, Olmos D and de Bono JS: Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69:4937–4940. 2009. View Article : Google Scholar
9	Attard G, Reid AH, A’Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration- resistant prostate cancer. J Clin Oncol. 27:3742–3748. 2009. View Article : Google Scholar
10	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
11	Ryan CJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA: Interim analysis (IA) results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract LBA 4518) ASCO. 2012.
12	Mezynski J, Pezaro C, Bianchini D, et al: Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. July 5–2012.(E-pub ahead of print). View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles